Watch the webinar “Benefits of 5KL When Outsourcing Late-phase Biologics Drug Substance Manufacturing” to learn more about:

  • Application data around performance and scalability
  • Process economy comparison with traditional stainless steel bioreactors
  • Decision criteria that could be helpful in choosing between different cell culture strategies

Featured Speaker

Matt Zustiak

Director, Cell Culture Development, Pharma Services Group
Thermo Fisher Scientific

Matthew is currently Director of the Cell Culture Development at Patheon, part of Thermo Fisher Scientific, based in St. Louis, MO. He joined the group in 2013 and has lead the upstream development and tech transfer of numerous phase I-III programs for both mAbs and non-mAbs produced in mammalian cells. This included both standard fed-batch processes as well as perfusion based processes for unstable molecules including enzymes and blood factors. Prior to Joining Patheon Matt worked as a Scientist in the Cell Culture Development group for MedImmune. He joined MedImmune after completing his graduate work in Chemical and Biomolecular engineering at Johns Hopkins University. Matt found his passion for biotherapeutic protein production at the National Cancer Institute where he worked under a contract with Science Applications International Corporation (SAIC) in the Biopharmaceutical Development Program. He Joined SAIC after completing his undergraduate work in Chemical Engineering at the University of Michigan.


Register now for this webinar